Emergent BioSolutions (EBS) Misses Q2 EPS, Revenue
Tweet
Share
E-mailGet Alerts EBS Hot Sheet
Price: $8.01 +2.04%
EPS Growth %: -31.3%
Financial Fact:
Weighted-average number of shares - diluted: 49.44M
Today's EPS Names:
CRWS, MEI, PODC, More
EPS Growth %: -31.3%
Financial Fact:
Weighted-average number of shares - diluted: 49.44M
Today's EPS Names:
CRWS, MEI, PODC, More
Join SI Premium – FREE
Emergent BioSolutions (NYSE: EBS) reported Q2 EPS of ($0.86), $1.24 worse than the analyst estimate of $0.38. Revenue for the quarter came in at $242.7 million versus the consensus estimate of $270.94 million.
For earnings history and earnings-related data on Emergent BioSolutions (EBS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Synopsys upgraded at Piper Sandler on Intel foundry momentum, Apple opportunity
- Cerebras Systems (CBRS) Misses Q1 EPS, Revenues Beat
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
